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The autocrine role of proteoglycan-4
(PRG4) in modulating osteoarthritic
synoviocyte proliferation and expression of
matrix degrading enzymes
Ali Alquraini1,6, Maha Jamal1, Ling Zhang2, Tannin Schmidt3, Gregory D. Jay2,4 and Khaled A. Elsaid5*
Abstract
Background: Lubricin/proteoglycan 4 (PRG4) is a mucinous glycoprotein secreted by synovial fibroblasts and
superficial zone chondrocytes. Recently, we showed that recombinant human PRG4 (rhPRG4) is a putative ligand for
CD44 receptor. rhPRG4-CD44 interaction inhibits cytokine-induced rheumatoid arthritis synoviocyte proliferation.
The objective of this study is to decipher the autocrine function of PRG4 in regulating osteoarthritic synoviocyte
proliferation and expression of catabolic and pro-inflammatory mediators under basal and interleukin-1 beta (IL-1β)-
stimulated conditions.
Methods: Cytosolic and nuclear levels of nuclear factor kappa B (NFκB) p50 and p65 subunits in Prg4+/+ and Prg4-/-
synoviocytes were studied using western blot. Nuclear translocation of p50 and p65 proteins in osteoarthritis (OA)
fibroblast-like synoviocytes (FLS) in response to IL-1β stimulation in the absence or presence of rhPRG4 was studied
using DNA binding assays. OA synoviocyte (5000 cells per well) proliferation following IL-1β (20 ng/ml) treatment in
the absence or presence of rhPRG4 (50–200 μg/ml) over 48 hours was determined using a colorimetric assay. Gene
expression of matrix metalloproteinases (MMPs), tissue inhibitor of metallproteinases-1 (TIMP-1), TIMP-2, IL-1β, IL-6, IL-
8, TNF-α, cycloxygenae-2 (COX2) and PRG4 in unstimulated and IL-1β (1 ng/ml)-stimulated OA synoviocytes, in the
presence or absence of rhPRG4 (100 and 200 μg/ml), was studied following incubation for 24 hours.
Results: Prg4-/- synoviocytes contained higher nuclear p50 and p65 levels compared to Prg4+/+ synoviocytes (p < 0.
05). rhPRG4 (100 μg/ml) reduced p50 and p65 nuclear levels in Prg4+/+ and Prg4-/- synoviocytes (p < 0.001). Similarly,
rhPRG4 (200 μg/ml) inhibited NFκB translocation and cell proliferation in OA synoviocytes in a CD44-dependent
manner (p < 0.001) via inhibition of IκBα phosphorylation. IL-1β reduced PRG4 expression in OA synoviocytes and
rhPRG4 (100 μg/ml) treatment reversed this effect (p < 0.001). rhPRG4 (200 μg/ml) reduced basal gene expression of
MMP-1, MMP-3, MMP-13, IL-6, IL-8, and PRG4 in OA synoviocytes, while increasing TIMP-2 and cycloxygenase-2 (COX2)
expression (p < 0.001). rhPRG4 (200 μg/ml) reduced IL-1β induction of MMP-1, MMP-3, MMP-9, MMP-13, IL-6, IL-8, and
COX2 expression in a CD44-dependent manner (p < 0.001).
Conclusion: PRG4 plays an important anti-inflammatory role in regulating OA synoviocyte proliferation and reduces
basal and IL-1β-stimulated expression of catabolic mediators. Exogenous rhPRG4 autoregulates native PRG4
expression in OA synoviocytes.
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Background
Lubricin/proteoglycan-4 (PRG4) is a glycoprotein secreted
by synovial fibroblasts and superficial zone chondrocytes
[1–3]. The importance of PRG4 to joint hemostasis is evi-
denced in the loss-of-function mutations in the Prg4 gene
in the autosomal recessive disease, camptodactylyl-
arthropathy-coxa vara pericarditis (CACP) syndrome, char-
acterized by juvenile-onset arthropathy [4, 5]. The joints of
Prg4 knockout (Prg4-/-) mice display progressive synovial
hyperplasia, cartilage surface fibrillations, and chondrocyte
apoptosis, which may not be completely reversed by PRG4
re-expression [6–8]. Therapeutically, the recombinant and
native forms of PRG4 have been shown to exhibit a
disease-modifying effect in pre-clinical osteoarthritis (OA)
models [9–14].
A biological role for recombinant human PRG4 (rhPRG4)
was recently reported. rhPRG4 was shown to compete with
hyaluronan for binding to the CD44 receptor resulting in
downstream inhibition of nuclear factor kappa B (NFκB)
nuclear translocation in synoviocytes from patients with
rheumatoid arthritis (RA) [15]. Furthermore, rhPRG4
inhibits cytokine-induced proliferation of murine Prg4-/-
synovial fibroblasts and human synovial fibroblasts derived
from patients with RA [15]. rhPRG4 has also been shown to
interact with toll-like receptors 2 and 4 (TLR2 and TLR4)
and may fulfill an anti-inflammatory role [15–17].
CD44 is a major cell surface receptor, with various iso-
forms generated by alternative splicing and glycosyla-
tions, which possesses the ability to bind different
ligands and exert different biological functions in inflam-
mation and cancer [18, 19]. Increased expression of
CD44 was reported in experimental OA and in cartilage
and synovia of patients with different severities of OA
[20–23]. Given the emerging evidence on the role of
PRG4 in regulating synoviocyte proliferation in response
to inflammatory stimuli, we sought to decipher the auto-
crine role of PRG4 in regulating OA synoviocyte prolif-
eration and expression of matrix metalloproteinases
(MMPs), tissue inhibitors of matrix metalloproteinases
(TIMPs), aggrecanase-1 (a disintegrin and metallopro-
teinase with thrombospondin motifs 4 (ADAMTS4)),
aggrecanase-2 (ADAMTS5), and pro-inflammatory and
chemotactic cytokines. Additionally, we studied the
regulation of PRG4 gene expression in OA fibroblast-
like synoviocytes (FLS) in response to interleukin-1 beta
(IL-1β) and rhPRG4 treatments. We hypothesized that
PRG4 is an important autocrine modulator of synovial
cells, mediated by its interaction with CD44.
Methods
NFκB p50 and p65 cytosolic and nuclear levels in Prg4+/+
and Prg4-/- synoviocytes and impact of rhPRG4 treatment
Synovial tissues were harvested from Prg4+/+ and Prg4-/-
male mice 8–10 weeks old and synoviocytes were
isolated as described [15]. Prg4+/+ and Prg4-/- synovio-
cytes were cultured in T-25 flasks until confluence. Prg4
+/+ and Prg4-/- synoviocytes were treated with rhPRG4
(100 μg/ml) [24], CD44 monoclonal antibody (CD44 Ab)
(1.25 μg/ml) (Abcam, USA) or a combination of rhPRG4
and CD44 Ab for 48 hours. Nuclear and cytosolic cell
extractions were performed using NE-PER nuclear and
cytoplasmic extraction reagents kit (Thermo Fisher Sci-
entific, USA). A total of 20 μg of protein was loaded into
the wells of 4–12% Bis-Tris gels (Thermo Fisher Scien-
tific) followed by gel electrophoresis and western blot-
ting. Membranes were blocked using 5% nonfat dry milk
in PBS-T for 1 hour at room temperature. Subsequently,
membranes were incubated with anti-NFκB p50 anti-
body (Santa Cruz Biotechnology, USA) (1:1000 dilution)
or anti-NFκB p65 antibody (Abcam) (1:1000 dilution)
overnight at 4 °C. Membranes were also incubated with
anti-Lamin B1 antibody (Abcam) (nuclear loading con-
trol) or anti β-Actin antibody (Cell signaling Technolo-
gies, USA) (cytosolic loading control). After washing
three times with PBS-T, membranes were incubated with
IRDye 800CW goat anti-rabbit secondary antibody
(1:10,000 dilution) (LI-COR, USA) at room temperature
for 1 hour. After washing three times with PBS-T, mem-
branes were imaged using Odyssey CLx imaging system
(LI-COR). Densitometry analysis was performed using
Image J software. Data are presented as the densitometry
ratio of p50 or p65 and either Lamin B1 or β-Actin in
the same sample. Data are presented as the average ±
standard deviation of three independent experiments.
IL-1β induced NFκB p50 and p65 nuclear translocation in
OA FLS, and IL-1β induced cell proliferation and impact of
rhPRG4 treatment
OA FLS (Cell Applications, USA) were harvested from
patients undergoing total knee replacement. Cells were
used between the third and sixth passages in all experi-
ments. OA FLS (300,000 cells per well) were stimulated
with IL-1β (20 ng/ml; R&D Systems, USA) for 6 hours
at 37 °C in the presence or absence of rhPRG4 (100 μg/
ml), rhPRG4 (200 μg/ml), rhPRG4 (200 μg/ml) + CD44
Ab (2.5 μg/ml; Abcam) or CD44 Ab (2.5 μg/ml). Cells
were harvested and nuclear extraction was performed
using a commercially available kit (Thermo Fisher Scien-
tific). Total protein was quantified, and 3 μg of nuclear
extract from each experimental group was used. The
p50 and p65 proteins were detected in the nuclear
extract using NFκB DNA binding assay kits (Abcam).
Data are presented as p50 or p65 nuclear levels normal-
ized to untreated controls. Data are presented as the
average ± the standard deviation of four independent ex-
periments, each with duplicate wells per group.
OA FLS were seeded in T-25 flasks at 1,000,000 cells
in DMEM+ 10% FBS for 48 hours. The total volume
Alquraini et al. Arthritis Research & Therapy  (2017) 19:89 Page 2 of 15
was 4 ml. After 48 hours, medium was removed and re-
placed with DMEM+ 1% FBS. Cells were incubated for
6 hours in the absence or presence of rhPRG4 (100 and
200 μg/ml) and/or CD44 Ab (2.5 μg/ml; pre-treatment
for 2 hours prior to rhPRG4 treatment) followed by
treatment with IL-1β (1 ng/ml) for 30 minutes.
Subsequently, medium was removed and cells were
rinsed twice with ice cold PBS (1 ml). Protein extraction
reagent (M-PER, Thermo Fisher Scientific) supple-
mented with protease and phosphatase cocktail inhibitor
(1:100 dilution; Thermo Fisher Scientific) and EDTA
(1:100 dilution; Thermo Fisher Scientific) was added
(300 μl per flask) and cells were collected. Protein sam-
ples (20 μg/ml; 40 μl per well) were loaded in 10% PAGE
pre-cast gels (Bio-Rad, USA). Following gel electrophor-
esis and transfer, membranes were blocked using 5% bo-
vine serum albumin (BSA) for 1 hour at room
temperature. Membranes were probed for phosphory-
lated inhibitor kappa B alpha (p-IκBα) or total IκBα
using commercially available rabbit antibodies (Abcam).
Antibodies were diluted 1:1000 in 5% BSA and incu-
bated with membranes overnight at 4 °C. After washing
with Tris-buffered saline Tween 20 (TBS-T), membranes
were incubated with horseradish peroxidase (HRP)-con-
jugated goat anti-rabbit (1:5000) for 1 hour at room
temperature. Membranes were also probed for β-Actin
using a commercially available β-Actin antibody (1:
10,000) (Abcam). Protein bands were developed using
SuperSignal West Pico PLUS chemiluminescent sub-
strate (Thermo Fisher Scientific) and visualized using C-
Digit Target (LI-COR, USA).
OA FLS in 96-well plates (5000 cells per well) in
DMEM supplemented with 1% FBS and 1 mM pyruvate
were stimulated with IL-1β (20 ng/ml) for 48 hours at
37 °C in the absence or presence of rhPRG4 at a final
concentration of 50, 100, or 200 μg/ml. The total volume
in each well was 200 μl. Cell proliferation was deter-
mined using the Cell Titer 96 AQueous one solution cell
proliferation assay (MTS; Promega, USA) and absorb-
ance at 490 nm was measured. In a separate set of
experiments, rhPRG4 (200 μg/ml) treatment was per-
formed in the absence or presence of a CD44 Ab
(2.5 μg/ml; Abcam) and cell proliferation was deter-
mined as described previously. Data are presented as
fold of OA FLS proliferation normalized to untreated
controls. Data are presented as the average ± standard
deviation of four independent experiments, each with
triplicate wells per group.
Modulation of PRG4 secretion by OA FLS and RA FLS and
impact of rhPRG4 on PRG4 gene expression in
unstimulated and IL-1β stimulated OA synoviocytes
OA FLS and RA FLS (Cell Applications) were grown in
DMEM+ 10% FBS and used between the third and sixth
passages: 20,000 cells per well were plated in sterile 96-
well plates and incubated at 37 °C for 48 hours to allow
cell attachment. The total volume per well was 200 μl.
The medium was changed to DMEM+ 1% FBS and cells
were treated with IL-1β (1 ng/ml), tumor necrosis factor
alpha (TNF-α) (1 ng/ml; R&D Systems), or transforming
growth factor beta (TGF-β) (1 ng/ml; R&D Systems) for
72 hours. Subsequently, medium supernatants were col-
lected and PRG4 concentrations were determined using
an inhibition ELISA as previously described [16]. PRG4
concentrations were normalized to cell density, deter-
mined colorimetrically using the Cell Titer 96 AQueous
one solution cell proliferation assay (MTS; Promega)
and the 490 nm absorbance was measured. Data are
presented as media PRG4 content normalized to cell
density. Data are presented as the average ± standard
deviation of four independent experiments, each with
duplicate wells per group.
OA FLS (250,000 cells per well) were treated with IL-
1β (1 ng/ml) in the absence or presence of rhPRG4 (100
or 200 μg/ml) for 24 hours followed by RNA extraction
using Triazol reagent (Thermo Fisher Scientific), and
RNA concentrations were determined using a NanoDrop
ND-2000 spectrophotometer (NanoDrop Technologies,
USA). cDNA was synthesized using Transcriptor First
Strand cDNA Synthesis Kit (Roche, USA). Quantitative
PCR (qPCR) was performed on Applied Biosystems
StepOnePlus Real-Time PCR System (Thermo Fisher
Scientific) using TaqMan Fast Advanced Master Mix
(Life Technologies, USA). The cycle threshold (Ct) value
of PRG4 (Hs00981633_m1; Thermo Fisher Scientific)
was normalized to the Ct value of GAPDH
(Hs02758991_g1; Thermo Fisher Scientific) in the same
sample, and the relative expression was calculated using
the 2-ΔΔCt method [25]. In another set of experiments,
rhPRG4 (100 and 200 μg/ml) was incubated with OA
FLS for 24 hours followed by RNA isolation, cDNA syn-
thesis, and PRG4 qPCR as described above. Data are
presented as fold PRG4 gene expression compared to
untreated control. Data are presented as the average plus
on minus standard deviation of four independent experi-
ments with duplicate wells per treatment.
Modulation of IL-1β-induced OA FLS proliferation by OA
SF and the role of synovial fluid PRG4
Synovial fluid (SF) samples were collected from patients
with OA (n = 5) (Articular Engineering, USA) following
knee replacement surgery [16]. Four of the OA patients
were female and the median age of the group was
65 years. OA SF was pooled from the five patients.
PRG4 immunoprecipitation was conducted as described
previously [16]. PRG4 depletion was confirmed by assay-
ing pooled OA SF for PRG4 levels using an inhibition
ELISA as previously described [16].
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IL-1β-induced OA FLS proliferation was conducted as
described previously in the absence or presence of
pooled OA SF or PRG4-immunoprecipitated OA SF at
20 μl or 40 μl per well (corresponding to 10% or 20%
dilution). Cell proliferation was determined using the
Cell Titer 96 AQueous one solution cell proliferation
assay (MTS; Promega) and the 490 nm absorbance was
measured. Data are presented as fold OA FLS prolifera-
tion compared to untreated controls. Data are presented
as the average ± standard deviation of four independent
experiments, each with duplicate wells per treatment.
PRG4 knockdown in OA FLS and proliferation of PRG4-
silenced OA FLS
OA FLS (250,000 cells per well) were treated with a pre-
validated PRG4 small interfering RNA (siRNA) (Thermo
Fisher Scientific) (25 pmol per well) or a non-targeted
negative control (NC) siRNA (25pmoles) (Thermo Fisher
Scientific) for 48 hours. Transfection was performed using
Lipofectamine RNAiMAX (Thermo Fisher Scientific) per
manufacturer’s recommendations. To confirm PRG4
knockdown, PRG4 gene expression was determined in
PRG4 siRNA and NC siRNA-treated OA FLS as described
previously and compared to PRG4 gene expression in
untreated control OA FLS. IL-1β stimulation of OA FLS
proliferation in control, NC siRNA, and PRG4 siRNA-
treated cells was performed as described previously. IL-1β
stimulation was performed for 24 hours and cell prolifera-
tion was measured as described previously. OA FLS prolif-
eration of the different experimental groups was
normalized to untreated control cells. Data are presented
as the average ± standard deviation of three independent
experiments with duplicate wells per treatment.
Impact of rhPRG4 treatment on target gene expression in
unstimulated and IL-1β-stimulated OA FLS
OA FLS (250,000 cells per well) were treated with
rhPRG4 (100 and 200 μg/ml) for 24 hours followed by
RNA isolation, cDNA synthesis and qPCR was per-
formed as described previously. Target genes included
MMP-1 (Hs00899658_m1), MMP-2 (Hs00234422_m1),
MMP-3 (Hs00968305_m1), MMP-9 (Hs00234579_m1),
MMP-13 (Hs00233992_m1), TIMP-1 (Hs00171558_m1),
TIMP-2 (Hs00234278_m1), ADAMTS4 (Hs00192708_m
1), ADAMTS5 (Hs00199841_m1), IL-1β (Hs00174097_m
1), IL-6 (Hs00985639_m1), IL-8 (Hs00174103_m1), TNF-
α (Hs00174128_m1), and cycloxygenase-2 (COX2) (HS0
0153133_m1). All primers and probes are commercially
available (Thermo Fisher Scientific). The Ct values of
target genes were calculated and normalized to the Ct
value of GAPDH in the same sample and relative gene
expression was calculated as described previously. Data
are presented as fold expression of target genes in
rhPRG4-treated OA FLS compared to expression in
untreated control OA FLS. Data are presented as the
average ± standard error of the mean (SEM) of four
independent experiments.
OA FLS (250,000 cells per well) were treated with IL-
1β (1 ng/ml) in the absence or presence of rhPRG4 (100
and 200 μg/ml) for 24 hours followed by RNA isolation,
cDNA synthesis, and qPCR as described previously. Tar-
get genes included MMP-1, MMP-2, MMP-3, MMP-9,
MMP-13, TIMP-1, TIMP-2, ADAMTS4, ADAMTS5, IL-
1β, IL-6, IL-8, TNF-α and COX2. The Ct values of target
genes were calculated and normalized to the Ct value of
GAPDH in the same sample, and relative gene expres-
sion was calculated as described previously. Data are
presented as fold expression of target genes in the IL-1β
group, IL-1β + rhPRG4 (100 μg/ml) or IL-1β + rhPRG4
(200 μg/ml)-treated OA FLS groups, compared to
expression in the control group. Data are presented as
the average ± SEM of four independent experiments.
In another set of experiments, CD44 neutralization was
achieved by pre-incubating OA FLS (250,000 cells per well)
with CD44 Ab (2.5 μg/ml; Abcam) for 2 hours followed by
treating OA FLS with IL-1β + rhPRG4 (200 μg/ml) for
24 hours followed by RNA isolation, cDNA, and qPCR as
described previously. Data are presented as the average ±
SEM of four independent experiments.
Statistical analyses
The nuclear NFκB p50 and p65 protein levels in OA FLS
treatments were normalized to untreated control levels. The
average of the absorbance values in untreated control cells
across the four independent experiments was used to
normalize absorbance values in the different experimental
groups across the four independent experiments. A similar
approach was used to present OA FLS proliferation. Statis-
tical analyses of gene expression data was performed using
ΔCt values (Ct target gene-Ct GAPDH) for each gene of
interest in each experimental group and data were graphic-
ally presented as fold expression relative to untreated con-
trols using the 2-ΔΔCt method. Continuous variables were
initially tested for normality and equal variances. Variables
that satisfied both assumptions were tested for statistical sig-
nificance using Student’s t test or analysis of variance
(ANOVA) with Tukey’s post-hoc test for comparisons of
two groups and more than two groups, respectively. Vari-
ables that did not satisfy the normality assumption were
tested using the Mann-Whitney U test or ANOVA on the
ranks. The level of statistical significance was set at α= 0.05.
Results
Cytosolic and nuclear NFκB p50 and p65 proteins in Prg4
+/+ and Prg4-/- synoviocytes and impact of rhPRG4
treatment
Cytosolic and nuclear p50 in rhPRG4 and CD44 anti-
body (Ab)-treated and untreated synoviocytes is shown
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in Fig. 1. A representative blot of p50 protein, cytosolic
and nuclear loading controls is shown in Fig. 1a. We
have observed stronger p50 bands in the cytosolic and
nuclear fractions of Prg4-/- synoviocytes compared to
Prg4+/+ cells. Consistently, rhPRG4 treatment reduced
cytosolic and nuclear p50 levels in both Prg4+/+ and
Prg4-/- synoviocytes. Semi-quantitative analysis of nor-
malized cytosolic and nuclear p50 band intensities from
the different experimental groups is presented in Fig. 1b
and c. Cytosolic and nuclear p50 subunit levels were sig-
nificantly higher in Prg4-/- synoviocytes compared to
Prg4+/+ synoviocytes (p < 0.05). There was no significant
difference in cytosolic and nuclear levels of p50 between
untreated control and CD44 Ab-treated Prg4+/+ synovio-
cytes or Prg4-/- synoviocytes. rhPRG4 treatment signifi-
cantly reduced cytosolic and nuclear p50 levels
compared to untreated control Prg4+/+ and Prg4-/-
synoviocytes (p < 0.001). A trend towards an increase in
cytosolic and nuclear p50 levels in the CD44 Ab + rhPRG4
group compared to the rhPRG4 alone group was observed
although it was not statistically significant (p > 0.05).
Cytosolic and nuclear p65 protein in rhPRG4 and
CD44 Ab-treated and untreated synoviocytes is shown
in Fig. 2. p65 protein was detectable in the cytosolic and
nuclear fractions in Prg4+/+ and Prg4-/- synoviocytes
(Fig. 2a). rhPRG4 treatment consistently reduced p65
staining intensity in the cytosolic and nuclear fractions
in both genotypes. Semi-quantitative analysis of normal-
ized cytosolic and nuclear p50 band intensities from the
different experimental groups is presented in Fig. 2b and
c. Nuclear p65 subunit levels were significantly higher in
Prg4-/- synoviocytes compared to Prg4+/+ synoviocytes
(p < 0.01). CD44 Ab-treated Prg4-/- synoviocytes had sig-
nificantly higher nuclear p65 levels compared to untreated
A
B C
Fig. 1 The impact of recombinant human proteoglycan 4 (rhPRG4) treatment on cytosolic and nuclear levels of nuclear factor kappa B (NFκB)
p50 subunit in Prg4+/+ and Prg4-/- synoviocytes; *p < 0.001, **p < 0.01, ***p < 0.05. a Representative western blot showing cytosolic and nuclear
p50 protein in Prg4+/+ and Prg4-/- synoviocytes in control, CD44 antibody (CD44 Ab)-treated, CD44 Ab + rhPRG4-treated and rhPRG4-treated cells.
Lamin B1 was used as a nuclear loading control and β-Actin was used as a cytosolic loading control. b Semi-quantitative densitometry analysis of
normalized cytosolic p50 protein in untreated and rhPRG4-treated Prg4+/+ and Prg4-/- synoviocytes. Prg4-/- synoviocytes had higher cytosolic p50
compared to Prg4+/+ synoviocytes. rhPRG4 (100 μg/ml) reduced cytosolic p50 levels in Prg4+/+ and Prg4-/- synoviocytes. Co-incubation with CD44
Ab (1.25 μg/ml) did not alter the effect of rhPRG4. Data are presented as mean ± standard deviation of three independent experiments. c Semi-
quantitative densitometry analysis of normalized nuclear p50 protein in untreated and rhPRG4-treated Prg4+/+ and Prg4-/- synoviocytes. Prg4-/-
synoviocytes had higher nuclear p50 compared to Prg4+/+ synoviocytes. rhPRG4 (100 μg/ml) reduced nuclear p50 levels in Prg4+/+ and Prg4-/-
synoviocytes. Co-incubation with CD44 Ab (1.25 μg/ml) did not alter the effect of rhPRG4. Data are presented as mean ± standard deviation
of three independent experiments
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controls (p < 0.01). rhPRG4 treatment significantly
reduced cytosolic and nuclear p65 levels compared to
untreated control Prg4+/+ and Prg4-/- synoviocytes (p <
0.001). Similarly, a trend towards an increase in cytosolic
and nuclear p65 levels in the CD44 Ab + rhPRG4 group
compared to the rhPRG4 alone group was observed
although it was not statistically significant (p > 0.05).
rhPRG4 inhibited IL-1β-stimulated NFκB p50 and p65 nuclear
translocation in OA FLS mediated by inhibition of IκBα
phosphorylation in a CD44-dependent manner
IL-1β treatment significantly increased NFκB p50 and
p65 nuclear levels in OA FLS compared to untreated
OA FLS (p < 0.001) (Fig. 3a and b). rhPRG4 (100 μg/ml)
treatment significantly reduced IL-1β-induced p50 and
p65 nuclear translocation (p < 0.01). Similarly, rhPRG4
(200 μg/ml) treatment significantly reduced IL-1β
induced p50 and p65 nuclear translocation (p < 0.001).
There was no significant difference in the p50 and p65
nuclear level in the IL-1β + CD44 Ab group and the IL-
1β group. NFκB p50 and p65 nuclear levels in the IL-1β
+ rhPRG4 (200 μg/ml) + CD44 Ab group were signifi-
cantly higher than corresponding levels in the IL-1β +
rhPRG4 (200 μg/ml) group (p < 0.001) and were not sig-
nificantly different from nuclear levels in the IL-1β +
CD44 Ab group. The ability of rhPRG4 to lower NFκB
nuclear levels was inhibited by co-incubation with CD44
Ab, which showed no difference from the IL-1β group.
A representative p-IκBα western blot in control and IL-
1β-treated OA FLS in the presence or absence of rhPRG4
with or without CD44 Ab co-treatment is shown in Fig. 3c.
IL-1β treatment increased p-IκBα levels compared to un-
treated control. rhPRG4 (200 μg/ml) treatment reduced
IκBα phosphorylation compared to IL-1β alone. This effect
A
CB
Fig. 2 The impact of recombinant human proteoglycan 4 (rhPRG4) treatment on cytosolic and nuclear levels of nuclear factor kappa B (NFκB)
p65 subunit in Prg4+/+ and Prg4-/- synoviocytes; *p < 0.001, **p < 0.01, ***p < 0.05. a Representative western blot showing cytosolic and nuclear
p65 protein in Prg4+/+ and Prg4-/- synoviocytes in control, CD44 antibody (CD44 Ab)-treated, CD44 Ab + rhPRG-treated, and rhPRG4-treated cells.
Lamin B1 was used as a nuclear loading control and β-Actin was used as a cytosolic loading control. b Semi-quantitative densitometry analysis
of normalized cytosolic p65 protein in untreated and rhPRG4-treated Prg4+/+ and Prg4-/- synoviocytes. rhPRG4 (100 μg/ml) reduced cytosolic p65
levels in Prg4+/+ and Prg4-/- synoviocytes. Co-incubation with CD44 Ab (1.25 μg/ml) did not alter the effect of rhPRG4. Data are presented as
mean ± standard deviation of three independent experiments. c Semi-quantitative densitometry analysis of normalized nuclear p65 protein in
untreated and rhPRG4-treated Prg4+/+ and Prg4-/- synoviocytes. Prg4-/- synoviocytes had higher nuclear p65 compared to Prg4+/+ synoviocytes.
rhPRG4 (100 μg/ml) reduced nuclear p65 levels in Prg4+/+ and Prg4-/- synoviocytes. Co-incubation with CD44 Ab (1.25 μg/ml) did not alter the
effect of rhPRG4. Data are presented as mean ± standard deviation of three independent experiments
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was reversed by a CD44 Ab. We did not observe a differ-
ence in p-IκBα level between the IL-1β group and the IL-
1β +CD44 Ab group. A representative total IκBα western
blot in control and IL-1β-treated OA FLS in the presence
or absence of rhPRG4 with or without CD44 Ab co-
treatment is shown in Fig. 3d. IL-1β treatment reduced
total IκBα. Total IκBα was higher with IL-1β + rhPRG4
(200 μg/ml) compared to IL-1β alone. Co-incubation with a
CD44 Ab abolished the effect of rhPRG4 on total IκBα fol-
lowing IL-1β stimulation. We did not observe a difference
in total IκBα content between the IL-1β group and the IL-
1β +CD44 Ab group.
rhPRG4 inhibited IL-1β-stimulated proliferation in OA FLS
in a CD44-dependent manner
IL-1β induced OA FLS proliferation over 48 hours (p <
0.001) (Fig. 4a). rhPRG4 (50 μg/ml) treatment did not
reduce IL-1β-induced OA FLS proliferation. In contrast,
rhPRG4 (100 and 200 μg/ml) treatments significantly
reduced IL-1β-induced OA FLS proliferation (p < 0.01; p
< 0.001). CD44 Ab and rhPRG4 co-treatment resulted in
significantly greater OA FLS proliferation compared to
rhPRG4 treatment (p < 0.01) and was not significantly
different from OA FLS proliferation in the IL1β alone
group. Finally, there was no significant difference in OA
FLS proliferation between the IL-1β + CD44 Ab group
and the IL-1β group.
Modulation of PRG4 production in OA FLS and RA FLS
and effect of rhPRG4
Basal PRG4 production in OA FLS was significantly
higher than PRG4 production by RA FLS (p < 0.001)
(Fig. 4b). IL-1β and TNF-α reduced PRG4 production by
OA FLS compared to control untreated cells (p < 0.001).
A B
C D
Fig. 3 The impact of recombinant human proteoglycan 4 (rhPRG4) treatment on interleukin-1 beta (IL-1β)-induced nuclear factor kappa b (NFκB) p50
and p65 nuclear translocation, inhibitor kappa B alpha (IκBα) phosphorylation and degradation. Data are presented as mean ± standard deviation of
four independent experiments; *p < 0.001, **p < 0.01. a Impact of rhPRG4 treatment on IL-1β-induced p50 protein nuclear translocation in ostoarthritis
fibroblast-like synoviocytes (OA FLS). IL1β treatment induced p50 protein nuclear translocation. rhPRG4 treatment (100 μg/ml and 200 μg/ml) inhibited
IL-1β-induced p50 protein nuclear translocation. Co-incubation with a CD44 neutralizing monoclonal antibody (CD44 Ab) abolished the effect of
rhPRG4 treatment. CD44 Ab treatment alone did not alter p50 nuclear translocation. b Impact of rhPRG4 treatment on IL-1β-induced p65 protein
nuclear translocation in OA FLS. IL1β treatment induced p65 protein nuclear translocation. rhPRG4 treatment (100 μg/ml and 200 μg/ml) inhibited IL-
1β-induced p65 protein nuclear translocation. Co-incubation with a CD44 neutralizing monoclonal antibody (CD44 Ab) abolished the effect of rhPRG4
treatment. CD44 Ab treatment alone did not alter p65 nuclear translocation. c Representative western blot of cytosolic phosphorylated inhibitor kappa
B alpha (p-IκBα) in untreated and IL-1β-treated OA synoviocytes in the absence or presence of rhPRG4 and/or CD44 Ab. rhPRG4 (200 μg/ml) reduced p-
IκBα levels in a CD44-dependent manner. d Representative western blot of cytosolic total inhibitor kappa B alpha (IκBα) in untreated and IL-1β-treated OA
synoviocytes in the absence or presence of rhPRG4 and/or CD44 Ab. rhPRG4 (200 μg/ml) increased IκBα levels in a CD44-dependent manner
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TGF-β enhanced PRG4 production by OA FLS com-
pared to control untreated cells (p < 0.001). IL-1β, TNF-
α, and TGF-β did not significantly alter PRG4 produc-
tion by RA FLS compared to untreated cells.
rhPRG4 (100 μg/ml) treatment did not alter basal
PRG4 gene expression in OA FLS (Fig. 4c). In contrast,
rhPRG4 (200 μg/ml) significantly reduced PRG4 gene
expression in OA FLS (p < 0.001). IL-1β reduced PRG4
gene expression in OA FLS (p < 0.001). PRG4 expression
in the IL-1β + rhPRG4 (100 μg/ml) group was signifi-
cantly higher than PRG4 expression in IL-1β alone (p <
0.001) and the IL-1β + rhPRG4 (200 μg/ml) group (p <
0.01). Alternatively, there was no significant difference in
PRG4 gene expression between the IL1β group and the
IL1β + rhPRG4 (200 μg/ml) group. Finally, PRG4 gene
expression in the IL-1β + rhPRG4 (200 μg/ml) treatment
was significantly lower than PRG4 expression in
untreated control OA FLS (p < 0.001).
SF PRG4 depletion and PRG4 downregulation promotes
OA FLS proliferation
Mean PRG4 concentration in OA SF after PRG4 immu-
noprecipitation was 25.11 ± 3.18 μg/ml, compared to
280.43 ± 14.76 μg/ml in OA SF with no PRG4 immuno-
precipitation. OA SF treatment at 10% dilution did not
significantly alter IL-1β-induced OA FLS proliferation
(Fig. 5a). PRG4-deficient OA SF (10% dilution) signifi-
cantly increased IL-1β-induced OA FLS proliferation
compared to OA SF (10% dilution) (p < 0.001) or no SF
treatment (p < 0.01). OA SF (20% dilution) significantly
reduced IL-1β-induced OA FLS proliferation (p < 0.01)
(Fig. 5b). PRG4-deficient OA SF (20% dilution)
Fig. 4 The impact of recombinant human proteoglycan 4 (rhPRG4) treatment on interleukin-1 beta (IL-1β)-induced osteoarthritis fibroblast-like
synoviocytes (OA FLS) proliferation and regulation of proteoglycan-4 (PRG4) gene expression and production. Data are presented as the average ±
standard deviation of four independent experiments; *p < 0.001, **p < 0.05. a Impact of rhPRG4 treatment (50, 100, and 200 μg/ml) on IL-1β-
induced proliferation of OA FLS over 48 hours. IL-1β induced OA FLS proliferation. rhPRG4 (100 and 200 μg/ml) reduced IL-1β-induced OA FLS
proliferation. Co-treatment with a CD44 neutralizing monoclonal antibody (CD44 Ab) abolished the effect of rhPRG4 treatment. CD44 Ab treatment
alone did not alter IL-1β-induced OA FLS proliferation. b Regulation of PRG4 production by cytokines in OA FLS and rheumatoid arthritis FLS (RA FLS).
OA FLS produces significantly higher PRG4 protein compared to RA FLS. IL-1β and TNF-α reduce PRG4 production by OA FLS while transforming
growth factor beta (TGF-β) increases PRG4 production by OA FLS. IL-1β, TNF-α, and TGF-β did not alter PRG4 production by RA FLS. c IL-1β downregulated
PRG4 gene expression in OA FLS. PRG4 expression in the IL-1 β+ rhPRG4(100 μg/ml) group was higher than PRG4 expression in the IL-1β alone group and
was not different from PRG4 expression in control cells. PRG4 expression in the IL-1β+ rhPRG4(200 μg/ml) group was lower than PRG4 expression in the
control and in the IL-1β+ rhPRG4(100 μg/ml) group. rhPRG4 (200 μg/ml) treatment reduced basal PRG4 gene expression in OA FLS compared to control.
Data are presented as fold change compared to untreated control OA FLS
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significantly increased IL-1β induced OA FLS prolifera-
tion compared to OA SF (20% dilution) or no SF treat-
ment (p < 0.001). NC siRNA treatment did not
significantly alter PRG4 gene expression in OA FLS
compared to untreated OA FLS (Fig. 5c). In contrast,
PRG4 siRNA treatment resulted in a significant reduc-
tion in PRG4 gene expression, approximating an 80% re-
duction (p < 0.001) compared to untreated or NC
siRNA-treated OA FLS. PRG4 siRNA-treated OA FLS
displayed significantly higher basal cell proliferation
compared to NC siRNA-treated OA FLS (p < 0.01) or
untreated OA FLS (p < 0.001) over 24 hours (Fig. 5d).
Similarly, and following IL-1β stimulation, PRG4 siRNA-
treated OA FLS had significantly higher proliferation
compared to NC siRNA-treated OA FLS or non-
silenced control OA FLS over 24 hours (p < 0.001).
Expression of OA-associated catabolic enzymes is affected
by rhPRG4 in unstimulated and IL-1β-stimulated OA FLS
rhPRG4 (100 μg/ml) did not significantly alter basal ex-
pression of MMP-1, MMP-2, MMP-3, MMP-9, MMP-
13, TIMP-1, TIMP-2, ADAMTS4, or ADAMTS5
(Fig. 6a). rhPRG4 (200 μg/ml) significantly reduced basal
expression of MMP-1, MMP-3, and MMP-13 (p <
0.001). The magnitude of reduction in gene expression
was approximately 45% for MMP-1 compared with 58%
for MMP-3 and 62% for MMP-13. rhPRG4 (200 μg/ml)
significantly increased basal expression of TIMP-2 (p <
Fig. 5 The role of proteoglycan 4 (PRG4) resident in synovial fluids from patients with osteoarthritis (OA) and produced by OA fibroblast-like synoviocytes
(OA FLS) in modulating interleukin-1 beta (IL-1β)-induced OA FLS proliferation. Data are presented as mean± standard deviation of at least three independent
experiments. OA FLS proliferation of the different experimental groups was normalized to untreated control cells; *p< 0.001, **p< 0.05. a Impact of synovial
fluid PRG4 depletion on cellular proliferation in an in vitro model of IL-1β-induced OA FLS proliferation over 48 hours. IL-1β induced OA FLS proliferation and
OA SF (10%) did not alter the effect of IL-1β on OA FLS. PRG4-depleted OA SF (OA SF – PRG4) enhanced the proliferative effect of IL-1β on OA FLS. b Impact
of synovial fluid PRG4 depletion on cellular proliferation in an in vitro model of IL-1β-induced OA FLS proliferation over 48 hours. IL-1β induced OA FLS
proliferation and OA SF (20%) significantly reduced IL-1β-induced OA FLS proliferation. PRG4 depletion reversed the effect of OA SF and enhanced the
proliferative effect of IL-1β on OA FLS. c PRG4 gene knockdown in OA FLS using PRG4 small interfering RNA (siRNA). Treatment with a non-targeting
negative control (NC) siRNA over a 48-hour period did not alter PRG4 gene expression. PRG4 siRNA treatment reduced endogenous PRG4 expression
in OA FLS. Data are normalized to PRG4 expression in untreated control OA FLS. d Impact of PRG4 knockdown on OA FLS proliferation under unstimulated
and IL-1β stimulated conditions. PRG4 knockdown enhanced OA FLS proliferation under basal conditions compared to NC treatment over 24 hours. PRG4
knockdown enhanced IL-1β-induced OA FLS proliferation compared to NC treatment over 24 hours
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0.001) (~50% increase) and did not alter the expression
of MMP-2, TIMP-1, ADAMTS4, or ADAMTS5.
IL-1β significantly induced MMP-1, MMP-3, MMP-9,
MMP-13, ADAMTS4, and ADAMTS5 gene expression
in OA FLS (p < 0.001) (Fig. 6b). rhPRG4 (100 μg/ml)
treatment significantly reduced ADAMTS5 expression
in IL-1β-stimulated OA FLS (p < 0.001) (~35% reduc-
tion) (Fig. 6c). rhPRG4 (200 μg/ml) treatment signifi-
cantly reduced MMP-1, MMP-3, MMP-9, MMP-13, and
ADAMTS5 expression in IL-1β-stimulated OA FLS (p <
0.001). The magnitude of reduction in gene expression
was approximately 51% for MMP-1 compared with 76%
for MMP-3, 49% for MMP-9, 77% for MMP-13, and 60%
for ADAMTS5. rhPRG4 (100 or 200 μg/ml) treatment
did not alter ADAMTS4 expression. Expression of
MMP-9, MMP-13 and ADAMTS5 genes was signifi-
cantly higher in the IL-1β + rhPRG4 + CD44 Ab group
compared to the IL-1β + rhPRG4 group (p < 0.001)
(Fig. 6d). In contrast, there was no significant difference
in fold expression of MMP-1 or MMP-3 between the IL-
1β + rhPRG4 + CD44 Ab group and the IL-1β + rhPRG4
group. Additionally, there was no significant difference
in fold expression of MMP-1, MMP-3 or MMP-13
between the IL-1β + rhPRG4 + CD44 Ab group and the
IL-1β group.
Expression of OA-associated inflammatory cytokines and
mediators is affected by rhPRG4 in unstimulated and IL-
1β-stimulated OA FLS
rhPRG4 (100 μg/ml) did not significantly alter basal
expression of IL-1β, IL-6, IL-8, TNF-α, and significantly
increased basal COX2 gene expression (p < 0.001) (~96%
increase) (Fig. 7a). rhPRG4 (200 μg/ml) significantly
reduced basal expression of IL-1β, IL-6 and IL-8 (p <
0.001) (~37%, 59%, and 73% decrease) and significantly
increased basal expression of COX2 (~61% increase) (p
< 0.001). rhPRG4 (100 or 200 μg/ml) did not alter basal
expression of TNF-α.
IL-1β significantly induced IL-1β, IL-6, IL-8, TNF-α,
and COX2 gene expression (p < 0.001) (Fig. 7b). There
Fig. 6 The impact of recombinant human proteoglycan-4 (rhPRG4) treatment on basal and IL-1β-induced gene expression of matrix metalloproteinases
(MMPs), aggrecanases 1 and 2 (ADAMTS4 and ADAMTS5), and tissue inhibitor of metalloproteinases (TIMPs) in OA fibroblast-like synoviocytes (OA FLS). Data
are presented as the average ± standard error of the mean (SEM) of four independent experiments. Data are represented as fold change compared to
untreated control OA FLS; *p< 0.001. a Effect of rhPRG4 treatment on basal gene expression in OA FLS. rhPRG4 (200 μg/ml) reduced expression of MMP1,
MMP3, and MMP13. rhPRG4 (200 μg/ml) increased expression of TIMP-2. b Impact of IL-1β treatment on catabolic enzyme gene expression in OA FLS. IL-1β
induced MMP1, MMP3, MMP9, MMP13, TIMP-1, ADAMTS4, and ADAMTS5 gene expression. c Impact of rhPRG4 treatment in IL-1β-stimulated OA FLS. rhPRG4
(200 μg/ml) treatment reduced MMP1, MMP3, MMP9, MMP13 and ADAMTS5 gene expression in IL-1β-stimulated OA FLS. d Role of CD44 in modulating
the effect of rhPRG4 on MMP1, MMP3, MMP9, MMP-13, and ADAMTS5 expression in IL-1β-stimulated OA FLS. CD44 neutralization using a CD44 monoclonal
antibody (CD44 Ab) significantly inhibited the effect of rhPRG4 treatment on MMP9, MMP13, and ADAMTS5 expression
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was no significant difference in IL-1β, IL-6, IL-8, TNF-α,
or COX2 gene expression between the IL-1β + rhPRG4
(100 μg/ml) group and the IL-1β group (Fig. 7c).
rhPRG4 (200 μg/ml) treatment significantly reduced IL-
6, IL-8, and COX2 gene expression in IL-1β-stimulated
OA FLS (p < 0.001). The magnitude of reduction in gene
expression was approximately 67% for IL-6 compared
with 55% for IL-8 and 73% for COX2. Expression of IL-6,
IL-8 and COX-2 genes was significantly higher in the IL-
1β + rhPRG4 + CD44 Ab group compared to the IL-1β +
rhPRG4 group (p < 0.001) (Fig. 7d). Finally, there was no
significant difference in fold expression of IL-6, IL-8, or
COX-2 between the IL-1β + rhPRG4 + CD44 Ab group
and the IL-1β group.
Discussion
In this work, we have shown that nuclear levels of NFκB
p50 and p65 in Prg4-/- synoviocytes were higher com-
pared to Prg4+/+ synoviocytes. Additionally, Prg4+/+ and
Prg4-/- synoviocytes had similar levels of p65 subunits in
the cytosol while the latter had elevated cytosolic p50
subunit levels. Enhanced nuclear localization of NFκB in
Prg4-/- synoviocytes may explain their pro-inflammatory
and proliferative capacity under unstimulated conditions
and in response to inflammatory stimuli compared to
their wildtype counterparts [15]. rhPRG4 inhibited NFκB
p50 and p65 nuclear translocation in Prg4-/- synoviocytes
and Prg4+/+ synoviocytes. Interestingly, rhPRG4 treat-
ment reduced cytosolic levels of p50 and p65 proteins in
Prg4+/+ and Prg4-/- synoviocytes. This is a unique bio-
logical effect of rhPRG4 and may indicate that rhPRG4
functions to reduce the total cellular pool of NFκB, ac-
counting for its anti-proliferative and anti-inflammatory
activities. The observed effect of rhPRG4 in relation to
nuclear NFκB translocation in murine synoviocytes may
not be entirely due to its binding to CD44 receptor as
neutralization of CD44 did not completely abolish the
effect of rhPRG4.
OA synovitis is characterized by synovial hyperplasia
with an increased number of synovial lining cells,
neovascularization and inflammatory cell infiltration
[26–31]. Patients with OA display a heterogeneous array
of synovial pathologic changes and the severity of OA
synovitis is correlated with pain and disease progression
Fig. 7 The impact of recombinant human proteoglycan-4 (rhPRG4) treatment on basal and IL-1β-induced gene expression of IL-1β, IL-6, IL-8, TNF-α, and
cyclooxygenase-2 (COX2) in osteoarthritis fibroblast-like synoviocytes (OA FLS). Data are presented as the average ± standard error of the mean of four
independent experiments. Data are presented as fold change compared to untreated control OA FLS; *p < 0.001. a Effect of rhPRG4 treatment on basal
gene expression in OA FLS. rhPRG4 (100 μg/ml and 200 μg/ml) increased basal COX2 expression. rhPRG4 (200 μg/ml) reduced basal IL-1β, IL-6, and IL-8
expression. b Impact of IL-1β treatment on pro-inflammatory cytokines and mediators of gene expression in OA FLS. IL-1β induced IL-1β, IL-6, IL-8, TNF-
α, and COX2 gene expression. c Impact of rhPRG4 treatment in IL-1β-stimulated OA FLS. rhPRG4 (200 μg/ml) treatment reduced IL-1β, IL-6, IL-8, TNF-α,
and COX2 gene expression in IL-1β-stimulated OA FLS. d Role of CD44 in modulating the effect of rhPRG4 on IL-6, IL-8, and COX2 expression in IL-1β-
stimulated OA FLS. CD44 neutralization using a CD44 monoclonal antibody (CD44 Ab) significantly inhibited the effect of rhPRG4 treatment on IL-6, IL-8,
and COX2 expression
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[32–35]. OA synoviocytes proliferate in response to IL-1
as shown by us and others [36]. As expected, the degree
of OA synoviocyte proliferation in our experiment was
markedly reduced compared to RA synoviocyte prolifera-
tion under similar conditions [15, 36]. rhPRG4 dose-
dependently reduced IL-1-induced OA synovial fibroblast
proliferation, mediated by inhibition of NFκB p50 and p65
nuclear translocation, in a CD44-dependent manner. The
biological effect of rhPRG4 is mediated by its ability to in-
hibit IκBα phosphorylation subsequent to IL-1 receptor
stimulation. IκBα binds to NFκB subunits causing their
cytoplasmic retention [37]. Phosphorylation of IκBα results
in proteasome-mediated degradation [37]. rhPRG4 prevents
IκBα degradation in a CD44-dependent manner; this is
consistent with its ability to inhibit IL-1-induced NFκB nu-
clear translocation. This observation extends the efficacy of
rhPRG4 as a biologic agent that inhibits synoviocyte prolif-
eration in RA and OA, and establishes a role for CD44 in
modulating OA synoviocyte proliferation [38]. The role of
PRG4 in modulating OA synoviocyte proliferation is fur-
ther highlighted by the ability of PRG4 in SF to reduce OA
synoviocyte proliferation. Depleting PRG4 in OA SF en-
hanced the proliferative effect of IL-1 on OA synoviocytes.
PRG4 acts in an autocrine manner to inhibit OA synovio-
cyte proliferation. This effect is manifested by the enhanced
basal and IL-1-induced OA synoviocyte proliferation in re-
sponse to PRG4 knockdown. This autocrine role for PRG4
validates the synovial hyperplasia observed in Prg4-/- mice
and the partial regression of synovial hyperplasia upon Prg4
re-expression [5, 8].
PRG4 expression by articular chondrocytes and
synovial fibroblasts is modulated by mechanical and bio-
logical stimuli. Shear upregulates PRG4 gene expression
in articular cartilage [39, 40] and intermittent hydrostatic
pressure application enhances PRG4 expression in isolated
rat mandibular fibroblasts [41]. Cartilage biosynthesis of
PRG4 is reduced as a result of IL-1β and TNF-α exposure
but is increased with TGF-β [42–44]. In synoviocytes,
PRG4 expression is reduced by IL-1β and is increased by
TGF-β and TGF-β-linked PRG4 accumulation is counter-
balanced by IL-1β [42, 45]. In our study, IL-1β and TNF-α
reduced PRG4 production in OA synoviocytes but did not
reduce PRG4 production in RA synoviocytes. Correspond-
ingly, TGF-β enhanced PRG4 production in OA synovio-
cytes but did not enhance it in RA synoviocytes. These
differences in synoviocyte production of PRG4
extends to basal conditions where OA synoviocytes
produced PRG4 to a greater extent compared to RA
synoviocytes. While the underlying mechanism of dif-
ferential production of PRG4 by synoviocytes from
different disease origins remains to be elucidated,
these phenotypic differences may contribute to the
enhanced proliferation and migration seen in RA
synoviocytes compared to OA synoviocytes [36].
rhPRG4 exhibited a bimodal concentration-dependent
response related to its ability to modulate PRG4 expres-
sion in IL-1β-stimulated OA synoviocytes. While rhPRG4
at a low concentration restored PRG4 expression in OA
synoviocytes following IL-1β challenge, rhPRG4 at a
higher concentration did not antagonize IL-1β downregu-
lation of PRG4 in OA synoviocytes. Moreover, exogenous
PRG4 appeared to directly regulate PRG4 production by
OA synoviocytes. At a low concentration, rhPRG4 treat-
ment did not change basal expression of PRG4 in OA
synoviocytes. Alternatively, exogenous PRG4 exhibited
negative feedback on PRG4 expression in OA synoviocytes
as rhPRG4 treatment downregulated basal PRG4 expres-
sion in OA synoviocytes. Our observations extend the un-
derstanding of how endogenous PRG4 expression is
modulated by exogenous PRG4 in articular cartilage and
in in vivo models of posttraumatic arthritis [14, 46].
Synoviocytes play an important role in driving OA
pathogenesis. OA synoviocytes express a wide-range of
matrix-degrading catabolic enzymes and cytokines. In
our study, and in response to IL-1β stimulation, OA
synoviocytes induced the expression of MMP-1, MMP-3,
MMP-9, MMP-13, TIMP-1, aggrecanase-1, aggrecanase-
2, IL-1β, TNF-α, IL-6, IL-8, and COX2. Our results are in
agreement with previous studies that reported on the
effect of IL-1β on OA synoviocytes [47, 48]. rhPRG4
dose-dependently reduced the expression of MMP-1,
MMP-3, MMP-9, MMP-13, aggrecanase-2, IL-6, IL-8,
and COX2 in IL-1β-stimulated OA synoviocytes. This
anti-inflammatory effect of rhPRG4 was partially medi-
ated by the CD44 receptor, as blocking this receptor
abolished the effect of rhPRG4 on MMP-9, MMP-13,
aggrecanase-2, IL-6, IL-8, and COX2 expression.
rhPRG4 dose-dependently downregulated basal
expression of OA-associated enzymes and cytokines.
Specifically, rhPRG4 downregulated the expression of
MMP-1, MMP-3, MMP-9, and MMP-13, which are in-
volved in synovial fibroblast proliferation and migration
[49, 50] and cartilage destruction. Interestingly, rhPRG4
reduced the expression of COX2 in IL-1β-stimulated OA
synoviocytes, whereas rhPRG4 marginally increased the
expression of COX2 in unstimulated OA synoviocytes.
The significance of this observation in the overall
biological effect of rhPRG4 remains to be elucidated.
In summary, we herein report on the biological effect
of PRG4 on fibroblast-like synoviocytes derived from pa-
tients with OA. To our knowledge, this is the first report
that delineates the biological role of PRG4 in regulating
OA synoviocyte function. Our study adds to existing
literature that describes a non-mechanical cartilage-
protective effect of PRG4 through upregulation of
hypoxia-inducible factor (HIF3α) [51]. An interesting
finding in our work is the role of CD44 in modulating
the biological activity of rhPRG4 in synoviocytes from
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different origins. While rhPRG4 functioned to reduce
basal NFκB nuclear levels in murine synoviocytes, this
effect did not appear to be mediated by the CD44 recep-
tor. Furthermore, rhPRG4 had equal efficacy in Prg4-/-
synoviocytes and Prg4+/+ synoviocytes, despite the fact
that Prg4-/- synoviocytes display enhanced CD44 protein
expression compared to Prg4+/+ synoviocytes [15]. The
CD44-dependent activity of rhPRG4 is clearly evident in
OA FLS following stimulation with IL-1. In this setting,
rhPRG4 inhibited IL-1-induced NFκB activation and
downstream expression of catabolic enzymes and
inflammatory cytokines in a CD44-dependent manner.
Our findings may be limited by the small number of
OA SF aspirates included in the study. Additionally, we
have not studied the biological effect of rhPRG4 on FLS
from patients with varying degrees of synovitis. A third
limitation of our study is that we cannot exclude the
possibility that other SF proteins were co-precipitated in
the PRG4 immunoprecipitation experiments.
Conclusion
PRG4 is a glycoprotein secreted by synovial fibroblasts that
regulates basal and IL-1-induced expression of matrix me-
talloproteinases that are involved in synovial proliferation
and cartilage destruction. The full-length recombinant form
of PRG4 inhibits proliferation of synovial fibroblasts through
a mechanism that involves the CD44 receptor. Additionally,
depletion of native PRG4 in OA SF stimulates synoviocyte
proliferation.
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